New Delhi: India’s pharmaceutical industry is accelerating its shift from low-cost generics to high-value medicines, complex chemistry and advanced therapies, with manufacturers investing in domestic production of active pharmaceutical ingredients (APIs) to reduce import dependence and strengthen global competitiveness, industry experts said.